[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100557070":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":31,"responsibleParty":104,"collaborators":19,"id":106,"slug":107,"hasResults":108,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":19,"eligibilityCriteria":112,"healthyVolunteers":108,"sex":113,"minAge":114,"maxAge":19,"enrollmentInfo":115,"targetDuration":19,"studyType":118,"phases":119,"briefSummary":121,"conditions":122,"keywords":19,"overallStatus":34,"whyStopped":19,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":138},{"fullName":5,"class":6},"EtiraRx Australia Pty Ltd","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"ERX-315","EXPERIMENTAL","Active investigational therapy",[13],"Drug: ERX-315",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Drug administered intravenously twice a week at increasing dose levels, with starting dose of 0.4mg\u002Fkg.",[9],null,[21],{"name":22,"affiliation":23,"role":24},"Rasha Cosman, MBBS","The Kinghorn Cancer Centre","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":19,"email":30},"Research Director","CONTACT","01 469 600 6603","contact@etira.life",[32,52,61,75,92],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Macquarie University Health","RECRUITING","Ryde","New South Wales","2109","Australia","AU",{"type":41,"coordinates":42},"Point",[43,44],151.1062,-33.8188,{"lat":44,"lon":43},[47,50],{"name":19,"role":28,"phone":48,"phoneExt":19,"email":49},"+61 (2) 9812 3000","reception@muh.org.au",{"name":51,"role":24,"phone":19,"phoneExt":19,"email":19},"Danusha Sabanathan, FRACP PhD",{"facility":53,"status":34,"city":54,"state":36,"zip":55,"country":38,"countryCode":39,"cosmosGeoPoint":56,"geoPoint":60,"contacts":19},"The Kinghorn Cancer Center","Sydney","2010",{"type":41,"coordinates":57},[58,59],151.20732,-33.86785,{"lat":59,"lon":58},{"facility":62,"status":34,"city":63,"state":36,"zip":64,"country":38,"countryCode":39,"cosmosGeoPoint":65,"geoPoint":69,"contacts":70},"Westmead Hospital","Westmead","2145",{"type":41,"coordinates":66},[67,68],150.98768,-33.80383,{"lat":68,"lon":67},[71,74],{"name":72,"role":28,"phone":73,"phoneExt":19,"email":19},"Jeremy Mo, MD","(02) 8890 6666",{"name":72,"role":24,"phone":19,"phoneExt":19,"email":19},{"facility":76,"status":34,"city":77,"state":78,"zip":79,"country":38,"countryCode":39,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"Cancer Research SA","Adelaide","South Australia","5000",{"type":41,"coordinates":81},[82,83],138.59863,-34.92866,{"lat":83,"lon":82},[86,90],{"name":87,"role":28,"phone":88,"phoneExt":19,"email":89},"Kelly Mead","08 8359 2565","admin@crsa.au",{"name":91,"role":24,"phone":19,"phoneExt":19,"email":19},"Rohit Joshi, MBBS, FRACP",{"facility":93,"status":34,"city":77,"state":78,"zip":94,"country":38,"countryCode":39,"cosmosGeoPoint":95,"geoPoint":97,"contacts":98},"Icon Cancer Centre Adelaide","5037",{"type":41,"coordinates":96},[82,83],{"lat":83,"lon":82},[99,102],{"name":19,"role":28,"phone":100,"phoneExt":19,"email":101},"08 8474 0220","admin.adelaide@icon.team",{"name":103,"role":24,"phone":19,"phoneExt":19,"email":19},"Anna Mislang, MBBS, FRACP",{"type":105,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100557070","phase-1-a-phase-1-trial-of-erx-315-in-participants-with-advanced-solid-tumors-100557070",false,"NCT06533332","A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors","A First-in-Human, Phase 1 Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of Escalating Doses of ERX-315 in Participants With Advanced Solid Tumors","Inclusion Criteria:\n\n* Patients must be at least 18 years of age at the time of signing the informed consent.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.\n* Patients must have histologically or cytologically confirmed solid tumor, primarily including but not limited to breast, ovarian, pancreatic, endometrial and hepatocellular carcinoma, that is advanced unresectable and\u002For metastatic disease for whom standard therapies do not exist or are no longer effective\n* Patients must have measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.\n* Adequate baseline organ function and hematologic function\n* Life expectancy \\>3 months\n\nExclusion Criteria:\n\n* Systemic anti cancer therapy within 4 weeks of first dose of study drug\n* Major surgery (as defined by the Investigator) within 4 weeks of first dose of study drug.\n* Uncontrolled intercurrent illnesses\n* Known history of LIPA deficiency, such as Wolman disease or Cholesterol ester storage disease.","ALL","18 Years",{"count":116,"type":117},36,"ESTIMATED","INTERVENTIONAL",[120],"PHASE1","This is a Phase 1 study to assess the safety of ERX-315 in patients with advanced solid tumors that have failed approved systemic therapies.",[123,124,125,126,127,128],"Advanced Solid Tumor","Metastatic Breast Cancer","Metastatic Ovarian Cancer","Metastatic Endometrial Cancer","Metastatic Liver Cancer","Metastatic Pancreatic Cancer","2026-05-27",{"date":131,"type":132},"2026-05-29","ACTUAL",{"date":134,"type":132},"2024-10-14",{"date":136,"type":117},"2027-06-30",{"name":5,"class":6},5]